+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bile Duct Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 215 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5915989
A recent report highlights that the global bile duct cancer treatment market is expected to witness a robust growth between 2024 and 2031. However, the market faces significant challenges, primarily driven by cost-related factors.

Rising Incidences of Bile Duct Cancer in North America

Bile duct cancer and liver cancer cases have seen a concerning increase in North America in recent years. It is estimated that approximately 6,000 individuals are diagnosed with bile duct cancer each year in the United States. Alarmingly, the majority of those affected fall within the age group of 70 to 75 years.

Bile Duct Cancer Treatment Market Dynamics

Advancements in endoscopic imaging techniques and minimally-invasive high-tech stone retrieval products have emerged as key drivers for the growth of the pancreatic and bile duct stone management market. This segment is expected to witness a double-digit CAGR in the coming years.

A notable observation is that Asians are more prone to contracting bile duct cancers compared to non-Hispanic blacks and whites. Currently, the primary line of therapy for bile duct cancers involves chemotherapy, and it is expected to maintain the largest market share in the foreseeable future as alternative treatment methods take time to gain acceptance.

The U.S. Food and Drug Administration (FDA) has initiated accelerated approvals to expedite the introduction of these therapies into the bile duct cancer treatment market, aiming to provide patients with faster access to treatments.

Cost as a Restraining Factor

One significant factor restraining the growth of the Bile Duct Cancer Treatment Market is the cost associated with cancer treatment. The American Society of Clinical Oncology has highlighted a significant disparity in cancer treatment costs between developed and developing countries. Furthermore, restrictions on importing prescription medicines into the United States from foreign countries exacerbate the issue.

These price disparities are likely to hinder the Bile Duct Cancer Treatment Market in the United States. While medical tourism has thrived in Asian economies such as India, Singapore, and Malaysia, the COVID-19 pandemic has imposed travel restrictions, impacting this avenue for affordable treatment.

Competitive Landscape

Key players in the Bile Duct Cancer Treatment Market include ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Celgene Corp, Bayer AG, and Boston Scientific Corporation. These companies play a pivotal role in advancing treatment options and addressing the challenges faced by the market.

For further insights and a comprehensive analysis of the Bile Duct Cancer Treatment Market, please refer to the full report.

Market Segmentation

The Bile Duct Cancer Treatment Market is segmented based on various attributes to provide a comprehensive understanding of the market dynamics and opportunities. The key segments include:

Treatment Type:

  • Gemcitabine Combination Therapy: Treatment involving the use of gemcitabine in combination with other medications.
  • 5-fluorouracil Combination Therapy: Treatment involving the use of 5-fluorouracil in combination with other medications.
  • Capecitabine Combination Therapy: Treatment involving the use of capecitabine in combination with other medications.
  • Gemcitabine Single Agent: Treatment with gemcitabine as a single therapeutic agent.

Services Spending:

  • Radiation Therapy: Treatment involving radiation therapy techniques.
  • Brachytherapy Services: Treatment involving brachytherapy techniques.
  • External Beam Radiation Therapy (EBRT): Treatment involving external beam radiation therapy techniques.
  • Surgery: Surgical interventions for the treatment of bile duct cancer.

Disease Indication:

  • Intrahepatic Bile Duct Cancer: Cancer located within the liver's bile ducts.
  • Extrahepatic Bile Duct Cancer: Cancer located outside the liver's bile ducts.
  • Perihilar Bile Duct Cancer: Cancer occurring at the perihilar region of the bile ducts.
  • Distal Extrahepatic Bile Duct Cancer: Cancer occurring at the distal end of the extrahepatic bile ducts.

Distribution Channel:

  • Hospital Pharmacies: Pharmaceuticals distributed through hospital-based pharmacies.
  • Retail Pharmacies: Pharmaceuticals available at retail pharmacies.
  • Online Pharmacies: Pharmaceuticals accessible through online platforms.

Region:

  • North America: Includes the United States and Canada.
  • Latin America: Encompasses countries in Central and South America.
  • Europe: Comprises European countries.
  • Asia Pacific (APAC): Covers countries in the Asia Pacific region.
  • Middle East Africa (MEA): Encompasses countries in the Middle East and Africa.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Bile Duct Cancer Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
3.1. Global Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Treatment
3.1.1.2. Services Spending
3.1.1.3. Radiation Therapy
3.1.1.4. Surgery
3.2. Global Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Intrahepatic Bile Duct Cancer
3.2.1.2. Extrahepatic Bile Duct Cancer
3.2.1.2.1. Perihilar Bile Duct Cancer
3.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
3.3. Global Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Online Pharmacies
3.4. Global Bile Duct Cancer Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
4.1. North America Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Treatment
4.1.1.2. Services Spending
4.1.1.3. Radiation Therapy
4.1.1.4. Surgery
4.2. North America Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Intrahepatic Bile Duct Cancer
4.2.1.2. Extrahepatic Bile Duct Cancer
4.2.1.2.1. Perihilar Bile Duct Cancer
4.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
4.3. North America Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
5.1. Europe Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Treatment
5.1.1.2. Services Spending
5.1.1.3. Radiation Therapy
5.1.1.4. Surgery
5.2. Europe Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Intrahepatic Bile Duct Cancer
5.2.1.2. Extrahepatic Bile Duct Cancer
5.2.1.2.1. Perihilar Bile Duct Cancer
5.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
5.3. Europe Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Treatment
6.1.1.2. Services Spending
6.1.1.3. Radiation Therapy
6.1.1.4. Surgery
6.2. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Intrahepatic Bile Duct Cancer
6.2.1.2. Extrahepatic Bile Duct Cancer
6.2.1.2.1. Perihilar Bile Duct Cancer
6.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
6.3. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
7.1. Latin America Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Treatment
7.1.1.2. Services Spending
7.1.1.3. Radiation Therapy
7.1.1.4. Surgery
7.2. Latin America Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
7.2.1.1. Intrahepatic Bile Duct Cancer
7.2.1.2. Extrahepatic Bile Duct Cancer
7.2.1.2.1. Perihilar Bile Duct Cancer
7.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
7.3. Latin America Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Treatment
8.1.1.2. Services Spending
8.1.1.3. Radiation Therapy
8.1.1.4. Surgery
8.2. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Intrahepatic Bile Duct Cancer
8.2.1.2. Extrahepatic Bile Duct Cancer
8.2.1.2.1. Perihilar Bile Duct Cancer
8.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
8.3. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Disease Indication Heat map
9.2. Manufacturer vs by Disease Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Hoffman-La Roche AG
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bristol-Myers Squibb Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Teva Pharmaceuticals Industries Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Eli Lilly and Company
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Novartis AG
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Sanofi
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Fresenius Kabi AG
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Mylan N.V.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Kyowa Hakko Kirin Co Ltd.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Intercept Pharmaceuticals, Inc.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Pfizer, Inc.
  • F. Hoffman-La Roche AG
  • Bristol-Myers Squibb Company
  • Teva Pharmaceuticals Industries Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Fresenius Kabi AG
  • Mylan N.V.
  • Kyowa Hakko Kirin Co Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Accord Healthcare Inc.
  • Delcath Systems Inc.
  • Celgene Corporation
  • Johnson & Johnson.

Methodology

Loading
LOADING...